JPWO2020076799A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020076799A5 JPWO2020076799A5 JP2021519595A JP2021519595A JPWO2020076799A5 JP WO2020076799 A5 JPWO2020076799 A5 JP WO2020076799A5 JP 2021519595 A JP2021519595 A JP 2021519595A JP 2021519595 A JP2021519595 A JP 2021519595A JP WO2020076799 A5 JPWO2020076799 A5 JP WO2020076799A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acids
- set forth
- sequence set
- linked amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862743507P | 2018-10-09 | 2018-10-09 | |
| US62/743,507 | 2018-10-09 | ||
| PCT/US2019/055155 WO2020076799A1 (en) | 2018-10-09 | 2019-10-08 | Anti-mertk antibodies for treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022512642A JP2022512642A (ja) | 2022-02-07 |
| JP2022512642A5 JP2022512642A5 (https=) | 2022-10-18 |
| JPWO2020076799A5 true JPWO2020076799A5 (https=) | 2022-10-18 |
Family
ID=68345048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021519595A Pending JP2022512642A (ja) | 2018-10-09 | 2019-10-08 | がんを治療するための抗ＭｅｒＴＫ抗体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20210395392A1 (https=) |
| EP (1) | EP3864046A1 (https=) |
| JP (1) | JP2022512642A (https=) |
| KR (1) | KR20210072059A (https=) |
| CN (1) | CN112839962A (https=) |
| WO (1) | WO2020076799A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112021020867A2 (pt) * | 2019-04-19 | 2022-01-04 | Genentech Inc | Anticorpos, ácido nucleico, vetor, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, usos do anticorpo, método de tratamento de um indivíduo com câncer e método para reduzir a depuração |
| JP2023506465A (ja) | 2019-12-13 | 2023-02-16 | アレクトル エルエルシー | 抗ＭｅｒＴＫ抗体及びその使用方法 |
| JP2023519962A (ja) * | 2020-03-31 | 2023-05-15 | アレクトル エルエルシー | 抗ｍｅｒｔｋ抗体及びその使用方法 |
| MX2023008744A (es) | 2021-01-29 | 2023-10-02 | Illimis Therapeutics Inc | Molecula de fusion que tiene actividad no inflamatoria inductora de la fagocitosis. |
| US20240279341A1 (en) | 2021-06-16 | 2024-08-22 | Alector Llc | Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof |
| JP2024527493A (ja) | 2021-06-16 | 2024-07-25 | アレクトル エルエルシー | 一価の抗ＭｅｒＴＫ抗体及びその使用方法 |
| EP4417625A4 (en) * | 2021-10-15 | 2026-01-14 | Chiome Bioscience Inc | ANTIBODY OR FRAGMENT THEREOF THAT BINDS SPECIFICALLY TO MERTK, AND ANTITUMORAL AGENT |
| CN114591431B (zh) * | 2022-05-11 | 2022-08-12 | 迈威(上海)生物科技股份有限公司 | 抗人gas6抗体或其抗原结合片段及其应用 |
| CN120484126B (zh) * | 2022-07-28 | 2025-11-18 | 乐普创一生物科技（上海）有限公司 | 抗MerTK抗体及其用途 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1210428B1 (en) | 1999-08-23 | 2015-03-18 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| ES2532399T3 (es) | 2003-03-05 | 2015-03-26 | Halozyme, Inc. | Glicoproteína hialuronidasa soluble (sHASEGP), proceso para prepararla, usos y composiciones farmacéuticas que la comprenden |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| US20120230991A1 (en) * | 2008-07-29 | 2012-09-13 | Douglas Kim Graham | Methods and compounds for enhancing anti-cancer therapy |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| NZ628923A (en) | 2009-11-24 | 2016-02-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| KR101970025B1 (ko) | 2011-04-20 | 2019-04-17 | 메디뮨 엘엘씨 | Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들 |
| HRP20201595T1 (hr) | 2011-11-28 | 2020-12-11 | Merck Patent Gmbh | Anti-pd-l1 protutijela i njihova uporaba |
| CN113967253A (zh) | 2012-05-15 | 2022-01-25 | 百时美施贵宝公司 | 通过破坏pd-1/pd-l1信号传输的免疫治疗 |
| HK1204557A1 (en) | 2012-05-31 | 2015-11-27 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-l1 |
| CN104968364A (zh) | 2012-12-03 | 2015-10-07 | 百时美施贵宝公司 | 强化免疫调变性Fc融合蛋白的抗癌活性 |
| JP6742903B2 (ja) | 2013-05-02 | 2020-08-19 | アナプティスバイオ インコーポレイティッド | プログラム死−１（ｐｄ−１）に対する抗体 |
| US9676853B2 (en) | 2013-05-31 | 2017-06-13 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-1 |
| CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
| EA034666B1 (ru) | 2013-09-13 | 2020-03-04 | Бейджин Свитзерланд Гмбх | Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела |
| MY184154A (en) | 2013-12-12 | 2021-03-23 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| SG10201900002QA (en) | 2014-01-24 | 2019-02-27 | Dana Farber Cancer Institue Inc | Antibody molecules to pd-1 and uses thereof |
| JP7211703B2 (ja) * | 2014-12-22 | 2023-01-24 | ザ ロックフェラー ユニバーシティー | 抗ｍｅｒｔｋアゴニスト抗体及びその使用 |
| EP3916017A1 (en) | 2014-12-22 | 2021-12-01 | PD-1 Acquisition Group, LLC | Anti-pd-1 antibodies |
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| WO2016197367A1 (en) | 2015-06-11 | 2016-12-15 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| WO2017020291A1 (en) | 2015-08-06 | 2017-02-09 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel anti-pd-l1 antibodies |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| KR102055396B1 (ko) | 2015-08-11 | 2019-12-12 | 우시 바이올로직스 (케이만) 인코포레이티드 | 신규한 항-pd-1 항체 |
| WO2017024515A1 (en) | 2015-08-11 | 2017-02-16 | Wuxi Biologics (Cayman) Inc. | Novel anti-pd-1 antibodies |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| CN114605548A (zh) | 2015-09-01 | 2022-06-10 | 艾吉纳斯公司 | 抗-pd-1抗体及其使用方法 |
| US10954301B2 (en) | 2015-12-14 | 2021-03-23 | Macrogenics, Inc. | Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof |
| MX2018007295A (es) | 2016-01-11 | 2019-03-28 | Armo Biosciences Inc | Interleucina 10 en la produccion de linfocitos t cd8+especificos para el antigeno y metodos de uso de estos. |
| WO2017132827A1 (en) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| JP2020526584A (ja) | 2017-06-28 | 2020-08-31 | ザ ロックフェラー ユニバーシティー | 抗ｍｅｒｔｋアゴニスト抗体−薬物コンジュゲートおよびその使用 |
-
2019
- 2019-10-08 WO PCT/US2019/055155 patent/WO2020076799A1/en not_active Ceased
- 2019-10-08 KR KR1020217013674A patent/KR20210072059A/ko not_active Withdrawn
- 2019-10-08 EP EP19794806.0A patent/EP3864046A1/en active Pending
- 2019-10-08 US US17/284,119 patent/US20210395392A1/en not_active Abandoned
- 2019-10-08 JP JP2021519595A patent/JP2022512642A/ja active Pending
- 2019-10-08 CN CN201980067679.7A patent/CN112839962A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7171617B2 (ja) | 抗ＳＩＲＰα抗体 | |
| US12384853B2 (en) | Anti-HER2/PD1 bispecific antibody | |
| JPWO2021194942A5 (https=) | ||
| JP2020501531A5 (https=) | ||
| JP2021520201A5 (https=) | ||
| JP2019500891A5 (https=) | ||
| AU2016306090A1 (en) | 5-bromo-2,6-di-(LH-pyrazol-l-yl)pyrimidin-4-amine for use in the treatment of cancer | |
| RU2018124319A (ru) | Новые антитела к клаудину и способы их применения | |
| KR20240145470A (ko) | 항-tigit 항체 및 항-pd-1/항-vegfa 이중특이적 항체를 포함하는 약제학적 조성물 및 용도 | |
| US20240101675A1 (en) | Dual binding antibodies, methods of producing dual binding antibodies, and uses thereof | |
| WO2023060277A1 (en) | Composition of multispecific antibodies targeting cdh17-expressing tumors and method of making and using thereof | |
| JP2024054284A (ja) | ガンの処置のための結合分子 | |
| WO2024119193A2 (en) | Mutant il-2 polypeptides and il-2 prodrugs | |
| CN112074540A (zh) | 细胞接合的结合分子 | |
| JP2025186381A (ja) | Ｃｄ１３７結合分子及びその使用 | |
| JPWO2020076799A5 (https=) | ||
| JP2023103352A5 (https=) | ||
| JPWO2019195452A5 (https=) | ||
| AU2019306113B2 (en) | Anti-human PD-L1 antibodies and their uses | |
| JPWO2020185722A5 (https=) | ||
| EP4722254A1 (en) | Anti-fgfr2/pd-1 bispecific antibody | |
| JP7811028B2 (ja) | ヒトｃｘｃｌ１６抗体およびその使用 | |
| IL321677A (en) | Anti-PDL1 antibodies, multispecific antibodies, and methods of use | |
| JPWO2022212876A5 (https=) | ||
| JPWO2023002390A5 (https=) |